La cadena de opciones muestra datos clave de las opciones de acciones de Fastly a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Fastly..

Fastly (NYSE:FSLY) Bolsa, Cadena de Opciones

FASTLY INC - CLASS A

Fastly

Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2024.

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

COIN

FSLY

GEHC

HUBS

Wall Street anticipa importantes reportes financieros. Expectativas para Deere, Fastly, GE HealthCare y HubSpot y Coinbase.

Acciones a seguir en Wall Street hoy: Deere, Fastly, GE HealthCare y más

Media

ATEN

IESC

Jim Cramer analiza el rendimiento de varias acciones estadounidenses y comparte sus recomendaciones clave. ¿Cuáles destacan y cuáles evitar?

Cramer respalda NextEra Energy (NEE) y descarta otras acciones: ¿cuáles tienen más potencial?

Fastly Inc

Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) shares fell over 5% on Thursday following concerns about strategic risks tied to its acquisition of CyberArk Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>).
The deal raises questions around integration challenges, limited synergy with core offerings, and potential pricing pressure in Palo Alto's existing portfolio.
KeyBanc Capital Markets analyst Eric Heath downgraded Palo Alto Networks <a target="_blank" href="https://www.benzinga.com/quote/PANW/analyst-ratings" rel="noreferrer noopener">from Overweight to Sector Weight</a>.
Heath is downgrading Palo Alto shares due to multiple strategic concerns following the CyberArk Software acquisition.
He sees limited synergy between identity and Palo Alto&#8217;s broader platform, which centers on network and SecOps.
The analyst also believes customers may prefer independent identity-focused vendors.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/07/46720855/palo-alto-network-cyberark-deal-a-strategic-home-run-says-analyst-but-panw-stock-falls-nearly-7-in-pre-market" rel="noreferrer noopener">Palo Alto Network-CyberArk Deal A &#8216;Strategic Home Run,&#8217; Says Analyst — But PANW Stock Falls Nearly 7% In Pre-Market</a>
Unlike previous expansions by Palo Alto Networks, this move doesn't align with a replacement cycle, first-mover advantage, or a natural product extension.
Additionally, recent feedback from customers and partners pointing to more aggressive pricing raises concerns about potential weakness in organic demand for the company's current NGS portfolio.
Heath says he would take a more constructive view if demand for NGS offerings drives stronger subscription growth, if AI agents become widely used and PAM is central to securing them, if CyberArk shows success through cross-selling or seamless integration with Prisma or Cortex to enhance identity security, or if there's a clear path to free cash flow margin expansion beyond 37.5%.
This apart, while Palo Alto Networks has a solid track record of integrating acquisitions, this CyberArk deal is significantly larger, introducing greater execution risk.
Heath agrees with Palo Alto's view that identity is a stable, entrenched segment unlikely to be disrupted by new players the way endpoint, SIEM, and firewall markets were. That said, this very entrenchment also limits Palo Alto's chances to unseat incumbents in areas like SSO/MFA and IGA, where vendors such as Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Ping, SailPoint, and others are firmly established.
He acknowledges expected pushback around CyberArk potentially operating as a standalone entity or "speedboat," which has worked well for Palo Alto in the past.
However, the analyst notes that the scale of this deal will likely necessitate deeper integration to deliver genuine innovation in identity security.
On the idea that Palo Alto can cross-sell CyberArk to its 80,000+ customers, Heath notes that some platformized clients have previously said CyberArk was too costly, but now see potential pricing relief. Others are hopeful the acquisition might enhance parts of Palo Alto's portfolio like CIEM in Prisma Cloud, RBAC, and ITDR within XSIAM.
PANW Price Action: Palo Alto Networks shares were down 5.03% at $173.83 at the time of publication on Thursday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/news/25/07/46706920/if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-this-much-today" target="_blank" rel="noreferrer noopener">If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today</a></li>
</ul>
Photo: Shutterstock

Equities

Analyst Ratings

Movers

General

CYBR

MSFT

OKTA

PANW

Palo Alto Networks Downgraded On Strategic Concerns Post CyberArk Deal; Stocks Slide Over 5%

Rumors

Watching CSX Corp; Shares Spike Higher, Traders Circulate CSX Is Said To Work With Goldman Sachs To Explore Options

WIIM

ABBV

ABBV stock has given up its prior gain. AbbVie shares were trading higher after the company raised 2025 guidance.

eXp World Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPI#NASDAQ">EXPI</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.07 by 114.29 percent. This is a 112.5 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $1.309 billion which beat the analyst consensus estimate of $1.301 billion by 0.64 percent. This is a 1.08 percent increase over sales of $1.295 billion the same period last year.

Earnings Beats

Earnings Misses

EXPI

eXp World Holdings Q2 Adj. EPS $(0.01) Misses $0.07 Estimate, Sales $1.309B Beat $1.301B Estimate

BLDR

BLDR stock has given up its prior loss. Builders FirstSource shares were trading lower after the company cut its FY2025 sales guidance below estimates.

Shares of telehealth company Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46688728/novo-nordisk-weight-loss-stock-eli-lilly-wegovy-ozempic">significant headwinds</a> for major pharmaceutical companies in the lucrative weight-loss drug market.
HIMS stock was up most of the day. <a href="https://www.benzinga.com/quote/HIMS" target="_blank" rel="noreferrer noopener">Check the latest price here.</a>
What To Know: The primary catalyst appears to be a guidance cut from Novo Nordisk, the maker of Ozempic and Wegovy. The Danish firm <a href="https://www.benzinga.com/news/health-care/25/07/46698418/whats-going-on-with-eli-lilly-stock-on-tuesday-3">lowered</a> its 2025 sales growth forecast, citing slower-than-expected U.S. adoption and increased competition from compounded drugs. 
This news has highlighted the disruptive role of companies like Hims &amp; Hers, which offer patients access to more affordable, compounded versions of GLP-1 medications.
Analysts and market reports suggest that Hims &amp; Hers is <a href="https://www.benzinga.com/markets/equities/25/07/46716995/novo-nordisk-charts-signal-weakness-amid-wegovy-warning-expert-says-couldve-played-out-very-differently-if-they-had-embraced-hims">directly benefiting</a> from the accessibility and pricing challenges plaguing branded drugs from both Novo Nordisk and its competitor, Eli Lilly. 
While the pharmaceutical giants grapple with reimbursement issues and combat what they term &#8220;copycat versions,&#8221; Hims has successfully positioned itself as a key player in the consumer-facing telehealth space for weight management.
Investors are now focused on the company's upcoming financial results. Hims &amp; Hers is scheduled to report its <a href="https://www.benzinga.com/quote/HIMS/earnings">second-quarter earnings</a> after the market closes on Monday, Aug. 4. The report will be a critical test of whether the company's strategic positioning is translating into the strong revenue and growth that the recent stock surge anticipates.
Benzinga Edge Rankings: A closer look at the stock&#8217;s quantitative profile via <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> highlights the factors driving investor enthusiasm. HIMS boasts exceptionally high scores for Momentum at 97.93 and Growth at 98.84, placing it in the top tier of publicly traded companies for these metrics. 
This powerful trend is confirmed by positive checkmarks across its short, medium, and long-term price trends. However, this performance comes at a premium. The stock receives a very low Value score of 8.55. 
This data combination paints a clear picture of a classic high-momentum growth stock that, while showing fundamental strength and market tailwinds, is considered expensive by traditional valuation standards.
HIMS Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, HIMS shares are trading higher by 1.04% to $65.94 on Thursday at publication. The stock has a 52-week high of $72.98 and a 52-week low of $13.47.
Read Also: <a href="https://www.benzinga.com/markets/earnings/25/07/46685132/ozempic-and-wegovy-maker-cuts-outlook-in-surprise-move-picks-new-ceo">Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO</a>
<h2 class="wp-block-heading">How To Buy HIMS Stock</h2>
By now, you're likely curious about how to participate in the market for Hims &amp; Hers Health — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option or sell a call option at a strike price above where shares are currently trading — either way, it allows you to profit from the share price decline.
Image: Shutterstock

Health Care

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Stock Up, Nearing All-Time High As Weight-Loss Giants Stumble

With investors <a href="https://www.benzinga.com/markets/economic-data/25/06/45971228/retail-sales-slump-more-than-expected-as-tariff-fears-hit-spending">concerned about overall economic stability</a> amid the Trump administration's tariff impact, they're not in a particularly generous mood. That may be the lesson learned the hard way by global pharmaceutical giant Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>). Despite delivering an earnings report that offered an encouraging view, it wasn't a perfect print. Subsequently, SNY stock dropped sharply, potentially presenting a bounce-back opportunity for intrepid contrarians.
For the second quarter, Sanofi reported adjusted <a href="https://www.benzinga.com/markets/earnings/25/07/46758881/sanofis-q2-earnings-fall-short-on-expectations-despite-21-jump-in-dupixent-sales">earnings per share of 1.59 euros</a> or 90 cents per American depositary receipt (ADR) shares. This figure missed analysts' consensus estimate of 96 cents. On the top line, the performance was better, with the drugmaker ringing up 9.99 billion euros or $11.33 billion. Unfortunately, this figure also narrowly missed the consensus estimate of $11.53 billion.
At first glance, a miss on both the top and bottom lines would ordinarily warrant volatility in the underlying security; hence, the red ink in SNY stock shouldn't be surprising. However, Sanofi brought to the table line items that warranted excitement.
In particular, the company's therapeutic Dupixent — a prescription medication used to treat certain inflammatory conditions like eczema and asthma — saw sales increase by 21.1% to 3.83 billion euros. As well, vaccine sales reached 1.21 billion euros, representing a 10.3% increase. Overall, per Sanofi CEO Paul Hudson, the company delivered 10.1% sales growth, thanks in large part to its nine newly launched medicines and vaccines seeing growth of 47.3%.
It&#8217;s also important to note that Sanofi CFO François Roger expressed confidence that the Trump tariffs will have little impact on the drugmaker in 2025. Much of this insulation is due to the company's inventory position in the U.S.
Unfortunately, these nuances did not convince investors to hold onto SNY stock, which dropped more than 8% during the afternoon hours.
<h2 class="wp-block-heading">Crimson-Stained SNY Stock Presents A Possible Discount For Contrarians</h2>
From a bird's-eye-view, SNY stock appears favorably priced. While Sanofi didn't meet headline numbers, that's also a snapshot in time. With encouraging results for its new therapeutics and vaccines, SNY would seem to have a reasonable case for upside. However, this perspective presupposes that the security was appropriately priced earlier and that it will eventually return to its rightful territory.
Frankly, we just don't know if that's objectively true or not. This perspective comes from our collective lived experience, that the market tends to overreact to both good and bad news. However, very few of us rarely stop to think about the broader implications. Share price and earnings are examples of continuous scalar signals. They're unbounded so they can theoretically rise indefinitely. By logical deduction, we cannot objectively determine what a "good price" is or what "bad earnings" means.
One of the very few discrete, objective truths that we can analyze in the equities sector is that, at the end of the day, the market is either a net buyer or a net seller.
Looking back at the last 10 weeks, what we know objectively about SNY stock is that the market voted to buy the security four times and sell six times. Throughout this period, SNY incurred a downward trajectory. For brevity, we can label this sequence as 4-6-D.
Granted, it may look absurd to compress the price magnitude of SNY stock into a simple binary code. But what we have accomplished here is to establish a behavioral picture of the security. From here, we can look back at how the market has historically responded to the 4-6-D sequence. Additionally, we can look back at other 10-week rolling sequences in our dataset (which in this case starts from January 2019) to capture a holistic demand profile:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>L10 Category</td>
<td>Sample Size</td>
<td>Up Probability</td>
<td>Baseline Probability</td>
<td>Median Return if Up</td>
</tr>
<tr>
<td>1-9-D</td>
<td>3</td>
<td>66.67%</td>
<td>53.64%</td>
<td>0.66%</td>
</tr>
<tr>
<td>2-8-D</td>
<td>7</td>
<td>42.86%</td>
<td>53.64%</td>
<td>2.73%</td>
</tr>
<tr>
<td>3-7-D</td>
<td>16</td>
<td>68.75%</td>
<td>53.64%</td>
<td>2.05%</td>
</tr>
<tr>
<td>3-7-U</td>
<td>3</td>
<td>0.00%</td>
<td>53.64%</td>
<td>N/A</td>
</tr>
<tr>
<td>4-6-D</td>
<td>37</td>
<td>62.16%</td>
<td>53.64%</td>
<td>1.49%</td>
</tr>
<tr>
<td>4-6-U</td>
<td>17</td>
<td>58.82%</td>
<td>53.64%</td>
<td>0.87%</td>
</tr>
<tr>
<td>5-5-D</td>
<td>63</td>
<td>57.14%</td>
<td>53.64%</td>
<td>1.77%</td>
</tr>
<tr>
<td>5-5-U</td>
<td>39</td>
<td>46.15%</td>
<td>53.64%</td>
<td>1.05%</td>
</tr>
<tr>
<td>6-4-D</td>
<td>18</td>
<td>61.11%</td>
<td>53.64%</td>
<td>1.55%</td>
</tr>
<tr>
<td>6-4-U</td>
<td>46</td>
<td>43.48%</td>
<td>53.64%</td>
<td>1.38%</td>
</tr>
<tr>
<td>7-3-D</td>
<td>5</td>
<td>40.00%</td>
<td>53.64%</td>
<td>2.98%</td>
</tr>
<tr>
<td>7-3-U</td>
<td>39</td>
<td>53.85%</td>
<td>53.64%</td>
<td>1.36%</td>
</tr>
<tr>
<td>8-2-U</td>
<td>25</td>
<td>52.00%</td>
<td>53.64%</td>
<td>2.04%</td>
</tr>
<tr>
<td>9-1-U</td>
<td>5</td>
<td>60.00%</td>
<td>53.64%</td>
<td>0.23%</td>
</tr>
</tbody>
</table>
</figure>
From the table above, the chance that a long position in SNY stock will be profitable on any given week is 53.64%, a small upward bias. This is effectively our null hypothesis, the assumption of no mispricing. However, our alternative hypothesis is that, because of the flashing of the 4-6-D sequence, this probability of upside stands at 62.16%. Therefore, the deck is hot in our favor and an incentive exists to place a bet.
Assuming the positive pathway, the median expected return off the 4-6-D sequence is a 1.49% move. Should the bulls maintain control for a second week, the expected median performance is an additional 1.08%. If SNY stock manages to finish this week at around $46, it would theoretically be on course to reach approximately $47.20.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31150503/SNY-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-1009772" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31150503/SNY-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31150503/SNY-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31150503/SNY-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31150503/SNY-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
However, given the magnitude of volatility, it's possible that — should a bounce back materialize — the upside move may be stronger than usual.
<h2 class="wp-block-heading">Putting The Data To Work</h2>
For aggressive traders, the 45.00/47.50 bull call spread expiring Aug. 15 could be an enticing idea. This transaction involves buying the $45 call and simultaneously selling the $47.50 call, for a net debit paid of $100 (the most that can be lost in the trade). Should SNY stock rise through the short strike price ($47.50) at expiration, the maximum profit is $150, a payout of 150%.
Of course, for this trade to pan out, SNY stock would have to deliver an above-average performance within a short time period. For a more conservative trade, you may consider the same call spread — 45.00/47.50 — but for the Sep. 19 expiration date. However, this will reduce the max payout to around 108%.
Either way, much will hinge on the reliability of the 4-6-D sequence as a predictive signal. Running a one-tailed binomial test reveals a p-value of 0.1509, which means that there's a 15.09% chance that the implications of the signal could materialize randomly rather than intentionally. That's not going to meet the threshold of statistical significance. However, I would argue that the signal is empirically intriguing given the context of the market's open, entropic system.
Further, SNY stock has a history of marching higher from extreme volatility, such as the late October 2023 selloff. So, there's another chance for the bulls to place a daring wager.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46736319/chkp-stock-earnings-implosion-offers-deep-value">Options Corner: Check Point Software&#8217;s Post-Earnings Implosion Opens Deep Value Opportunity For Speculators</a></li>
</ul>
Image: Shutterstock

Options

Politics

Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares are trading lower Thursday, after Baird downgraded the stock to Underperform and slashed its price target <a href="https://www.benzinga.com/pressreleases/25/07/b46681310/unitedhealth-group-re-establishes-full-year-outlook-and-reports-second-quarter-2025-results">from $312 to $198. </a>
What To Know: The downgrade follows ongoing concerns around the company&#8217;s Optum Health segment and broader headwinds across nearly all of UnitedHealth's business lines, <a href="https://www.cnbc.com/2025/07/31/baird-downgrades-unitedhealth-shares-cites-concerns-over-optum-health-business.html">according to CNBC.</a>
Baird analyst Michael Ha cited serious doubts about the long-term profitability of Optum Health's value-based care model. In a note published Wednesday, Ha pointed to the company's second-quarter results, which revealed a significant margin reset, with long-term value-based care margins reduced to 5%. The firm's internal modeling indicated an implied headwind of nearly 20% over three years under CMS's v28 changes to risk adjustment. Ha wrote that without meaningful offsets or mitigation strategies, and with re-coding back to pre-v28 levels considered unrealistic, he has little confidence in UnitedHealth's ability to maintain even 1% value-based care margins by 2026.
The company's second-quarter earnings report earlier this week intensified concerns. While revenue slightly beat expectations, earnings missed, and the full-year forecast came in well below Wall Street estimates. The result triggered a sell-off that has extended through the week. Shares are now down roughly 51% over the past six months and 47% year-to-date, drastically underperforming the broader market, which is up more than 5% and 8% over the same periods, respectively.
Baird also flagged new concerns across UnitedHealth's other business units, including Medicare Advantage, Community Group/HIX, Medicaid and Optum Insight. Even segments that were previously seen as margin drivers, like OptumInsight and OptumRx, are now viewed as facing greater operational challenges heading into 2026.
Despite the downgrade, broader sentiment among analysts remains largely positive. According to LSEG data, 19 out of 28 analysts covering the stock still rate it as a buy or strong buy. The average price target sits at approximately $346, suggesting more than 30% upside from current levels. However, Thursday's steep drop signals investors are reacting more strongly to Baird's lowered expectations and growing skepticism about the company's ability to stabilize margins and earnings over the next year.
UNH Price Action: UnitedHealth shares were down 6.54% at $248.66 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46746923/arm-holdings-explores-designing-its-own-chips-as-ai-demand-skyrockets-more-competition-for-nvidia">Arm Holdings Explores Designing Its Own Chips As AI Demand Skyrockets: More Competition For Nvidia?</a></li>
</ul>
Image Via Shutterstock.

UnitedHealth Shares Slide Over 5% After Baird Downgrade And Price Target Cut

<ul>
<li>Tech firms, rare earths companies met with White House officials on July 24</li>
<li>Navarro confirms meeting, aims for rapid US rare earths output</li>
<li>Tech firms encouraged to invest in rare earths sector, sources say</li>
<li>China's export halt highlights US supply chain vulnerabilities</li>
</ul>
July 31 (Reuters) - Top White House officials told a group of rare earths firms last week that they are pursuing a pandemic-era approach to boost U.S. critical minerals production and curb China's market dominance by guaranteeing a minimum price for their products, five sources familiar with the plan told Reuters.
The previously unreported July 24 meeting was led by Peter Navarro, President Donald Trump's trade advisor, and David Copley, a National Security Council official tasked with supply chain strategy. It included ten rare earths companies plus tech giants Apple <a href="https://workspace.refinitiv.com/web/apps/quotewebapi?RIC=AAPL.O">AAPL.O</a>, Microsoft <a href="https://workspace.refinitiv.com/web/apps/quotewebapi?RIC=MSFT.O">MSFT.O</a> and Corning <a href="https://workspace.refinitiv.com/web/apps/quotewebapi?RIC=GLW.N">GLW.N</a>, which all rely on consistent supply of critical minerals to make electronics, the sources said.
Navarro and Copley told the meeting that a floor price for rare earths <a href="reuters://REALTIME/verb=NewsStory/ric=nL4N3T70RF">extended to MP Materials</a><a href="https://workspace.refinitiv.com/web/apps/quotewebapi?RIC=MP.N">MP.N</a> earlier this month as part of a multibillion-dollar investment by the Pentagon was "not a one-off" and that similar deals were also in the works, the sources said.
U.S. critical minerals firms, which complain that <a href="reuters://REALTIME/verb=NewsStory/ric=nL3N3MW0MN">China's market dominance</a>makes investing in mining projects risky, have long sought a federally backed price guarantee.
Rare earths, a group of 17 metals used to make magnets that turn power into motion, and other critical minerals are used widely across the electronics sector, including the manufacture of cell phones and weapons.
The officials detailed Trump's desire to quickly boost U.S. rare earths output - through mining, processing, recycling and magnet production - in a manner that would evoke the speed of <a href="reuters://REALTIME/verb=NewsStory/ric=nL2N2EK28H">2020's Operation Warp Speed</a>, which developed the COVID-19 vaccine in less than a year.
Navarro confirmed the meeting to Reuters. He said the administration aims to "move in 'Trump Time,' which is to say as fast as possible while maintaining efficiency" to remedy perceived vulnerabilities in the U.S. critical minerals industry. Navarro did not comment on whether he mentioned the price floor at the meeting.
"Our goal is to build out our supply chains from mines to end use products across the entire critical mineral spectrum, and the companies assembled at the meeting have the potential to play important roles in this effort," Navarro said.
China - the world's largest producer of rare earths for more than 30 years - halted exports in March as part of a trade spat with Washington that showed some signs of easing late last month, even as the broader tensions remain.
Beyond the price floor, Navarro and Copley advised attendees to avail themselves of existing government financial support, including billions of dollars worth of incentives in <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3T10IT">Trump's tax and spending bill</a> approved on July 4, the sources said.
Copley did not immediately respond to a request for comment.
Apple <a href="reuters://REALTIME/verb=NewsStory/ric=nL4N3TC0XI">signed a supply deal with MP</a> after the Pentagon's investment this month. At the Washington meeting, Navarro and Copley said Trump would like to see more tech companies invest in the rare earths sector, either through seed investing or by making buyouts, all of the sources said.
Apple and Corning did not immediately respond to requests for comment. Microsoft declined to comment.
&nbsp;
EXPORT BAN REQUEST
While the attendees asked Navarro to support a ban on exports of equipment containing rare earth magnets to spur domestic recycling, Navarro told them he would push for that only after the U.S. rare earths industry is more developed so as not to prematurely give China leverage in the ongoing trade spat, according to the sources.
When asked about a potential ban, Navarro told Reuters: "All policy options are on the table. As President Trump loves to say, 'Let's see what happens.'"
Attendees included Phoenix Tailings, which is <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3R81CB">building a rare earths processing facility</a> in New Hampshire, Momentum Technologies, which developed a modular battery and magnet recycling system, Vulcan Elements, which has built a pilot facility for rare earth magnets, and rare earths recyclers REEcycle and Cyclic Materials.
"These guys are serious about fixing the problem," said Vulcan CEO John Maslin. "They want companies to partner."
Redwood Materials and Cirba Solutions, two of North America's largest battery recyclers, also attended.
TechMet, which invests in mining projects across the globe and in which the U.S. government holds a minority stake, also attended the meeting, as did Noveon, a Texas-based rare earths magnet company.
Phoenix, Momentum, Cirba, TechMet, Noveon, Cyclic, ReElement and REEcycle, all of which are privately held, did not immediately respond to requests for comment. Redwood declined to comment.
The administration officials plan to meet again with the companies in roughly four to six weeks, a truncated timeline aimed at underscoring the administration's desire to quickly support a U.S. minerals industry, the sources said.

Macro Economic Events

Economics

Market Vectors Rare Earth/Strategic Metals Etf

REMX

''Trump Administration To Expand Price Support For U.S. Rare Earths Projects; Trump Administration's Price Support For MP Materials Was Not A 'One-off' And Will Be Extended To Other Companies, Sources Say' - Reuters Exclusive

The Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>) surged to an all-time high Thursday morning, powered by blockbuster quarterly earnings from key holdings Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>). Here&#8217;s what investors <a href="https://www.benzinga.com/markets/tech/25/07/46760627/magnificent-seven-microsoft-meta-nvdia-earnings-sp500-market-cap">need to know</a>.
What To Know: The highly concentrated ETF tracks the performance of the seven stocks colloquially known as the &#8220;Magnificent Seven&#8221;: Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta and Microsoft.
The rally was ignited after Microsoft <a href="https://www.benzinga.com/markets/earnings/25/07/46738585/microsoft-q4-earnings-highlights-double-beat-ceo-says-cloud-and-ai-is-the-driving-force">reported</a> fourth-quarter revenue of $76.44 billion and EPS of $3.65, comfortably beating analyst expectations. 
The company <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46763834/microsoft-stock-is-trading-higher-thursday-whats-going-on">cited</a> exceptional growth in its Intelligent Cloud segment, with revenue up 26% year-over-year, driven by strong demand for its Azure and AI services. CEO Satya Nadella called &#8220;Cloud and AI the driving force&#8221; of business transformation.
Similarly, Meta Platforms <a href="https://www.benzinga.com/markets/earnings/25/07/46739277/meta-beats-q2-earnings-estimates-issues-strong-guidance-shares-surge-to-new-highs">impressed</a> Wall Street, reporting second-quarter revenue of $47.52 billion and an EPS of $7.14, crushing estimates. The social media giant also issued strong third-quarter revenue guidance and highlighted AI&#8217;s role in improving ad performance.
The stellar results from both tech titans prompted a wave of price target upgrades from <a href="https://www.benzinga.com/quote/META/analyst-ratings">analysts</a> at firms including Goldman Sachs, Morgan Stanley and Piper Sandler. 
The performance underscores the growing dominance of the Magnificent Seven, which now collectively account for over $19 trillion in market value and represent <a href="https://www.benzinga.com/markets/tech/25/07/46760627/magnificent-seven-microsoft-meta-nvdia-earnings-sp500-market-cap">35% of the S&amp;P 500</a>, solidifying their critical role in the broader market&#8217;s direction.
Adding to the market&#8217;s focus, fellow &#8220;Magnificent Seven&#8221; member Apple is <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46641166/apple-shares-edge-higher-ahead-of-q3-earnings-release">scheduled</a> to release its third-quarter financial results after the market closes today. 
These results will be closely scrutinized for updates on consumer hardware demand and the company&#8217;s highly anticipated AI roadmap.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46767695/wall-street-today-markets-thursday-meta-microsoft-pce-inflation-records">Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What&#8217;s Moving Markets Thursday?</a></li>
</ul>

AAPL

AMZN

GOOG

GOOGL

MAGS

NVDA

TSLA

MAGS ETF Hits Record High As Microsoft And Meta Earnings Fuel Tech Rally

Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) posted a <a href="https://www.benzinga.com/node/46737581">solid fiscal third-quarter</a> performance on Wednesday, boosted by continued growth in its automotive and IoT businesses.
However, a cautious fourth-quarter outlook and lingering concerns over handset market volatility tempered investor enthusiasm, sending shares down more than 7% in Thursday trading.
Analysts across Wall Street responded with cautious optimism. Rosenblatt Securities&#8217; Kevin Cassidy, who maintained a Buy rating and a $225 price forecast, described the quarter as a &#8220;solid beat&#8221;.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46242782/why-qualcomms-stock-isnt-soaring-like-its-rivals" rel="noreferrer noopener">Why Qualcomm&#8217;s Stock Isn&#8217;t Soaring Like Its Rivals</a>
While fourth-quarter projections may not inspire near-term excitement, Cassidy underscored Qualcomm&#8217;s strength in edge AI, backed by its multi-generation NPU roadmap. He trimmed his fourth-quarter forecast slightly to $10.65 billion in revenue and $2.85 EPS, and now expects fiscal 2025 revenue of $43.52 billion and EPS of $11.88.
Bank of America Securities analyst Tal Liani also reiterated a Buy with a $200 forecast, emphasizing Qualcomm&#8217;s progress in diversifying beyond smartphones.
While handset revenue was marginally below expectations due to mix and timing issues, automotive and IoT gains, up 21.3% and 23.7% respectively, provided an effective offset.
Liani sees handset revenue rebounding in the next quarter, with forward guidance implying aggregate third-quarter and fourth-quarter performance should beat Street expectations. He also pointed to a stronger-than-expected operating margin that contributed to a 5-cent EPS beat.
Liani noted that non-handset revenue now comprises 30% of QCT sales, up from 25% three years ago, and is projected to grow 16% in 2025 and 20% in 2026.
He highlighted strong design momentum in automotive, with 12 digital chassis wins and 50 new vehicle launches this year. IoT, meanwhile, is being propelled by AI PCs and smart glasses adoption.
However, Liani flagged China as a key risk, with the region accounting for 68% of QCT handset revenue. Qualcomm&#8217;s expanded relationship with Xiaomi (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) and leadership in the mid-to-high-end segment provide some insulation, but rising domestic competition, particularly from MediaTek, remains a threat.
He also pointed to Qualcomm&#8217;s longer-term ambitions in the data center space as a potential future catalyst. The company, which recently acquired Alphawave, is leveraging its CPU and NPU assets and has entered advanced talks with a major hyperscaler. Though material revenue from this push isn&#8217;t expected until 2028, Liani views it as a promising growth avenue.
J.P. Morgan&#8217;s Samik Chatterjee echoed these sentiments, reiterating an Overweight rating and a $200 price forecast. He noted that the strength in IoT and automotive helped counteract weaker handset performance.
With the fourth quarter guidance pointing to a handset recovery, Chatterjee anticipates combined third and fourth-quarter revenue to exceed prior forecasts.
Looking ahead, he forecasts continued momentum in Auto and IoT, projecting 35% and 20% growth respectively in fiscal 2025, with handset sales expected to rise 10%.
While Qualcomm faces a revenue headwind from the expected loss of Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) business, Chatterjee highlighted management&#8217;s confidence in non-Apple revenues.
He anticipates overall revenue growth will slow to single digits in fiscal 2026 and 2027, but expects non-Apple handset revenue, Auto, and IoT segments to drive a return to double-digit growth beyond that period.
While Qualcomm&#8217;s strong quarterly execution reinforces its diversification strategy and long-term AI positioning, near-term caution around the handset cycle and China exposure continues to cloud the outlook for some investors.
Price Action: QCOM stock is trading lower by 7.61% to $147.04 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46735554/marvell-stock-rebounds-on-ai-momentum-new-global-chip-partnership" target="_blank" rel="noreferrer noopener">Marvell Stock Rebounds On AI Momentum, New Global Chip Partnership</a></li>
</ul>
Photo via Shutterstock

Price Target

Reiteration

Tech

QCOM

XIACF

Qualcomm's China Exposure A Key Risk Despite Xiaomi Partnership: Analyst

DA Davidson analyst Michael Baker maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Neutral and raises the price target from $260 to $380.

CVNA

DA Davidson Maintains Neutral on Carvana, Raises Price Target to $380

United Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBCP#NASDAQ">UBCP</a>) reported quarterly earnings of $0.33 per share. This is a 10 percent increase over earnings of $0.30 per share from the same period last year. The company reported $7.985 million in sales this quarter. This is a 8.11 percent increase over sales of $7.386 million the same period last year.

UBCP

United Bancorp Q2 EPS $0.33 Up From $0.30 YoY, Sales $7.985M Up From $7.386M YoY

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam&#8217;s recent performance highlights the company&#8217;s strong position in <a href="https://www.benzinga.com/pressreleases/25/07/b46753079/alnylam-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights-recent-period">the competitive landscape.</a>
<ul class="wp-block-list">
<li>ALNY stock is testing its 52-week high. <a href="https://www.benzinga.com/quote/ALNY" target="_blank" rel="noreferrer noopener">Check the latest price here.</a></li>
</ul>
Alnylam Pharmaceuticals stock is surging on Thursday after the company reported upbeat second-quarter earnings and 2025 guidance.
The company reported a second-quarter 2025 adjusted earnings of 32 cents, down from 56 cents a year ago. Analysts estimated a<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener"> loss of 79 cents</a>.
The company reported quarterly sales of $773.69 million, up 17% year over year, beating the consensus of $638.55 million.
Alnylam Pharmaceuticals achieved global net product revenues for Amvuttra and Onpattro for the second quarter of $492 million and $53 million, respectively, representing $544 million in total TTR net product revenues and 77% total TTR growth compared to a year ago.
The company achieved approximately 1,400 ATTR-CM Patients on Amvuttra (vutrisiran) as of June 30, 2025.
Also Read: <a href="https://www.benzinga.com/news/legal/25/06/45797712/moderna-beats-alnylam-appeal-in-covid-vaccine-patent-case" target="_blank" rel="noreferrer noopener">Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case</a>
The company achieved global net product revenues for Givlaari and Oxlumo for the second quarter of $81 million and $47 million, respectively, representing $128 million in total Rare net product revenue and 24% total Rare growth year over year.
&#8220;Our first full quarter of AMVUTTRA sales in ATTR-CM provided a significant inflection in our TTR franchise revenues, with total net product revenues growing 64% year-over-year. While still early in the launch, we are very encouraged by the initial pace of uptake&#8230;,&#8221; said Yvonne Greenstreet, chief executive officer of Alnylam.
Guidance: &#8220;Based on the strong progress during the first half of 2025 and our confidence in the overall business for the rest of the year, we are raising our total net product revenue guidance range by 27% at the midpoint, driven by an upward revision to our TTR franchise revenue guidance,&#8221; Greenstreet added.
Alnylam raised its fiscal 2025 sales guidance from $2.7 billion-$3 billion to $3.3 billion-$3.55 billion compared to the consensus of $2.89 billion.
Total TTR net product revenues (Amvuttra and Onpattro) of $2.175 billion-$2.275 billion, up from <a target="_blank" href="https://www.benzinga.com/node/45179856" rel="noreferrer noopener">prior guidance of $1.6 billion-$1.725 billion</a>.
Total rare net product revenues (Givlaari and Oxlumo) of $475 million-$525 million, up from prior guidance of $450 million –&nbsp;$525 million.
Needham maintains Alnylam Pharmaceuticals with a Buy and raises the price <a target="_blank" href="https://www.benzinga.com/quote/ALNY/analyst-ratings" rel="noreferrer noopener">forecast from $377 to $478</a>.
Price Action: ALNY stock was up 15.9% at $393.71 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46760627/magnificent-seven-microsoft-meta-nvdia-earnings-sp500-market-cap" target="_blank" rel="noreferrer noopener">Magnificent Seven Now Worth Over $19 Trillion—And They Make Up 35% Of The S&amp;P 500</a></li>
</ul>
Photo: jittawit21/Shutterstock

Biotech

Large Cap

Guidance

ALNY

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

DA Davidson analyst Michael Baker maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Buy and raises the price target from $550 to $585.

ULTA

DA Davidson Maintains Buy on Ulta Beauty, Raises Price Target to $585

DA Davidson analyst Michael Shlisky maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Neutral and raises the price target from $100 to $112.

DA Davidson Maintains Neutral on Federal Signal, Raises Price Target to $112

SIMO

SIMO stock has given up its prior gain. Silicon Motion Technology shares were trading higher after the company reported better-than-expected Q2 financial results.

When a mother named TJ wrote to Suze Orman's "<a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-how-can-i-get-a-mega-retirement-account">Women &amp; Money</a>" podcast for help, she described a difficult situation: her 22-year-old daughter, a full-time student working weekends and part-time hours, had maxed out her credit cards — again.
Two years earlier, the daughter refinanced her car to pay off her credit cards, but following the death of her father, she slipped back into debt and now owes $15,000. Her credit accounts have been closed, and she's locked into a payment plan she can't afford. Struggling to cover even gas and personal expenses, she turned to her mother for help.
TJ said she refuses to help her daughter financially and asked Orman for guidance.
Don't Miss:
<ul class="wp-block-list">
<li>Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a></li>
</ul>
<a href="https://www.benzinga.com/personal-finance/management/25/07/46526633/thinking-about-lending-money-to-family-suze-orman-says-you-might-be-hurting-more-than-helping">Orman</a> didn't hold back. "Do exactly what you have been doing, TJ," she said. "It's just that simple. Obviously, this is a woman who needs to learn until she gets it, and the only way she's going to get it is by letting her suffer."
<h2 class="wp-block-heading">Tough Love, Financial Lessons</h2>
Orman&#8217;s advice may sound harsh, but it's rooted in a principle she has long preached: personal responsibility. For young adults, particularly <a href="https://www.benzinga.com/personal-finance/25/02/43893926/you-can-be-a-student-without-a-student-loan-dave-ramseys-advice-to-paying-cash-for-college">college students</a> or recent graduates, early financial mistakes can leave lasting scars — but they can also be powerful teaching moments. Orman often emphasizes that bailing out a financially irresponsible loved one might only delay the inevitable reckoning.
According to a U.S. News &amp; World Report <a href="https://money.usnews.com/credit-cards/articles/2023-college-student-credit-cards-survey">survey</a>, over 42% of college students carry credit card debt. Many use credit for essentials like books and housing, but nearly half report spending on nonessentials like dining out and impulsive shopping.&nbsp;
In TJ's daughter's case, a mix of emotional spending and financial missteps pushed her into a deep hole.
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
<h2 class="wp-block-heading">Why Credit Card Debt Hits Students So Hard</h2>
Credit cards can be useful tools for building credit, but only when used responsibly. Students are especially vulnerable to making mistakes. A missed or late payment can lead to fees, higher interest rates, and a <a href="https://www.benzinga.com/personal-finance/management/25/06/45972344/millions-of-americans-just-took-a-100-point-hit-to-their-credit-score-and-it-could-get-worse-as-student-loan-collections-resume">drop in credit score</a> — a black mark that can linger for years.
A lack of financial literacy compounds the issue. Only 27% of students surveyed by U.S. News correctly identified what "revolving a balance" means. And nearly one in five didn't realize that credit cards require regular monthly payments.
These misunderstandings can quickly snowball into real financial harm. Even a $2,000 balance on a card with 20% interest could take over two years to pay off with minimum payments — costing hundreds in interest alone.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
<h2 class="wp-block-heading">What Should Parents Do?</h2>
While TJ's instinct to withhold financial help may seem cold, Orman's response highlights the long-term benefits of letting young adults face the consequences of their choices. That doesn't mean parents can't help at all.&nbsp;
<a href="https://www.morganstanley.com/articles/sage-credit-advice-college-students">Morgan Stanley</a> suggests starting with open conversations about budgeting, the risks of debt, and the value of credit. Teaching financial basics early can help prevent bigger issues later.
Adding a student as an authorized user to a parent&#8217;s card or encouraging responsible use of a student credit card can be helpful — but only if the student understands how credit works.
<h2 class="wp-block-heading">Bottom Line</h2>
Orman's blunt advice isn't about punishment — it's about growth. Letting someone "suffer," as she puts it, may be the push they need to take ownership of their finances. For parents of <a href="https://www.benzinga.com/24/12/42467913/dave-ramsey-warns-against-hammock-parenting-7-2-million-able-bodied-men-arent-even-looking-for-work-and-its-not-their-fault">financially struggling adult children</a>, the lesson is clear: emotional support doesn't have to mean writing a check. Sometimes, the hardest part of helping is stepping back.
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

Personal Finance

'The Only Way She's Going To Get It Is By Letting Her Suffer' Suze Orman's Tough Advice For Mother Whose Daughter Maxed Out Her Credit Cards

DA Davidson analyst Gary Tenner maintains Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) with a Buy and raises the price target from $96 to $100.

DA Davidson Maintains Buy on Axos Financial, Raises Price Target to $100

DA Davidson analyst Manuel Navas maintains NBT Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTB#NASDAQ">NBTB</a>) with a Buy and raises the price target from $53 to $55.

NBTB

DA Davidson Maintains Buy on NBT Bancorp, Raises Price Target to $55

Press Releases

Fastly Unveils DDoS Attack Insights to Strengthen Protection and Security Transparency

Fastly Application Security Solutions Delivered 235% ROI Over Three Years

Fastly to Announce First Quarter 2025 Financial Results

Fastly Announces First Quarter 2025 Financial Results

Fastly Appoints Tara Seracka as Chief Legal Officer and Albert Thong as Chief Marketing Officer

Cerby Raises $40M Series B to Automate Identity Security at Scale

Fastly Research: Commerce Industry Attacks Double as Bots Represent More Than One-Third of All Traffic

Comments

Fastly

Fastly (FSLY) Opciones

Fastly (NYSE:FSLY) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL